Prolactin

About: Prolactin is a research topic. Over the lifetime, 22356 publications have been published within this topic receiving 609537 citations. The topic is also known as: lactotropin, & PRL,.

Function of the homeodomain protein GHF1 in pituitary cell proliferation

Abstract: Mutations that cause pituitary dwarfism in the mouse reside in the gene encoding the transcription factor growth hormone factor 1 (GHF1 or pit1). These dwarf mice (dw and dwJ) are deficient in growth hormone (GH) and prolactin (PRL) synthesis and exhibit pituitary hypoplasia, suggesting a stem cell defect. With antisense oligonucleotide technology, a cell culture model of this genetic defect was developed. Specific inhibition of GHF1 synthesis by complementary oligonucleotides led to a marked decrease in GH and PRL expression and to a marked decrease in proliferation of somatotrophic cell lines. These results provide direct evidence that the homeodomain protein GHF1 is required not only for the establishment and maintenance of the differentiated phenotype but for cell proliferation as well.

Ovarian and hypothalamic control of the daily surges of prolactin secretion during pseudopregnancy in the rat.

Abstract: Cervical stimulation in the rat institutes a pattern of prolactin secretion consisting of two daily surges, one diurnal and one nocturnal, which continue for the greater part of pseudopregnancy. This contrasts with the diestrous day 1–2 interval of the estrous cycle wherein prolactin levels are low and relatively unchanging. A variety of noxious procedures such as aortic cannulation and serial blood sampling, sham ovariectomy and sham surgical cuts in the hypothalamus selectively and temporarily suppresses the diurnal prolactin surges of pseudopregnancy; the nocturnal surges remained unaffected. In the absence of the ovaries (removed on day 0 of pseudopregnancy) the diurnal prolactin surges have disappeared no later than day 5, whereas the nocturnal surges are present at day 6 but have disappeared by day 10. Hypothalamic retrochiasmatic cuts abolish immediately both surges. These results demonstrate the existence of an apparently unique kind of neuroendocrine reflex, copulation-induced, which results in r...

Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels

Abstract: Summary OBJECTIVE Hyperprolactinaemia in humans may be associated with a high prevalence of obesity but the nature of this link is poorly defined. The aim of this study was to establish the relationship between hyperprolactinaemia and body weight in patients with prolactin-secreting pituitary tumours. DESIGN We conducted a retrospective study of prolactinoma patients treated at the Endocrine Institute of the Tel Aviv Medical Center, Israel, during the period 1989‐1996. Patients with clinically nonfunctioning pituitary macroadenomas (NFA) served as the control group. Data on demographic parameters, body weight before and during treatment, clinical presentation including history of weight fluctuations, tumour size as measured by computed tomography or magnetic resonance imaging, modalities and response to treatment, and pituitary function before and during treatment were recorded from medical files. PATIENTS Forty-two patients with prolactinomas (PR) and 36 patients with clinically non-functioning macroadenomas (NFA) comprised the study population. RESULTS Mean weight was 93 6 3·4 kg and 78 6 2·7 kg in male patients with PR and NFA respectively (P o 0·0007). Recent weight gain (8 to 22 kg) was a presenting symptom in 13 PR patients, whereas only one NFA patient had this clinical presentation (P o 0·001). Seventeen PR patients lost weight (mean change π8·3 6 1·5 kg, range π2‐28 kg), during prolactin lowering therapy, 11 of whom had entirely normalized prolactin levels. Fourteen of the 18 patients who did not lose weight still had elevated prolactin levels (P o 0·01). Weight loss in patients with PR could not be attributed to altered pituitary function nor to compression of the third ventricle. In contrast to PR, no significant weight loss was observed in NFA patients. CONCLUSION Weight gain and elevated body weight are frequently associated with prolactinomas regardless of a mass effect on the hypothalamus or pituitary function. In this series, weight loss was recorded in 70% of prolactinomas patients and in 90% of male patients who normalized their prolactin levels. We propose the inclusion of hyperprolactinaemia in the differential diagnosis of endocrine obesity and weight gain.

Prolactin and prolactin receptors are expressed and functioning in human prostate.

Abstract: Prolactin is widely expressed in different tissues, and it is presumed to have both local and systemic actions. In males it is known to influence reproductive functions but the significance and mechanisms of prolactin action in male accessory reproductive tissues are poorly understood. Here we show that prolactin acts as a direct growth and differentiation factor for human prostate, as measured by changes in DNA synthesis and epithelial morphology of organ cultures. Furthermore, we report the expression in human prostate of a short prolactin receptor form in addition to the long form, based upon ligand cross-linking studies and RT-PCR analysis of mRNA expression. The highest density of prolactin receptors was detected in the secretory epithelial cells by immunohistochemistry. Finally, we report that prolactin is locally produced in human prostate epithelium, as evidenced by marked prolactin immunoreactivity in a significant portion of prostate epithelial cells, with parallel expression of prolactin mRNA in human prostate. Collectively, these data provide significant support for the existence of an autocrine/paracrine loop of prolactin in the human prostate and may shed new light on the involvement of prolactin in the etiology and progression of neoplastic growth of the prostate.